U24CA271037
Cooperative Agreement
Overview
Grant Description
Michigan Center for Translational Cancer Proteogenomics - Abstract
This application aims to establish a Proteogenomic Data Analysis Center at the University of Michigan for the Clinical Proteomic Tumor Analysis Consortium (CPTAC). Our center is anchored at the Michigan Center for Translational Pathology and brings together a multi-disciplinary team of leading scientific experts in the foundational areas of proteomics, cancer genomics, immunomics, and integrative systems biology.
Our team established the foundations for precision oncology and proteogenomics at the University of Michigan and has a long history of successful inter-institutional collaborations. This positions us well to apply, working in close collaboration with other CPTAC groups, our innovative algorithms, comprehensive computational infrastructure, and expert knowledge to carry out high-impact translational proteogenomics research that is a core mission of the CPTAC.
We have developed a balanced approach for integrative proteogenomic analyses, with a blend of both state-of-the-art and novel pipelines and tools. Our analytics support dual purpose - to perform both cohort-wide and patient-centric (personalized) investigations – a unique future and a strength of our proposal.
Our experience in support of our real-time precision oncology program and past CPTAC efforts will ensure both the fidelity of detecting diverse proteogenomic cancer driver events and rigorous ascertainment of their biological implications. Both of these features are of paramount importance to understand disease mechanisms and discover prognostic markers and therapeutic targets.
Our proposed strategy combines well-established and innovative data analyses and modeling approaches, cognizant of continuing developments in the corresponding areas. In addition, we propose a conceptually novel approach of "Integrative Cellular Network Analysis" and advanced data visualization modules, capitalizing on recent advances in single-cell and spatial proteogenomics research.
These features will refine inference from the bulk tissue omics data in terms of tumor microenvironment, ploidy and cellularity, identification of cell of origin and clonal expansion, cell-cell interactions, distinguishing lineage versus cancer-specific biomarkers, and gene signatures associated with genetic and epigenetic alterations. Such precise and refined integrative analyses across genome and proteome data require advanced bioinformatics tools and stringent quality control measures.
Our integrated genome/transcriptome/proteome pipelines – already in wide use by the research community - will be further optimized for speed and accuracy and enhanced with data visualization and report generation capabilities for presenting the findings to cancer biologists in a transparent and readily-interpreted manner.
Furthermore, our extensive experience in the area of biomarker discovery and precision oncology, further enhanced through participation of our investigators in the EDRN, SPORE, and other NIH initiatives, puts us in a strong position to drive the biomarker prioritization work to select candidate cancer-specific proteins and peptides for subsequent targeted validation assays.
This application aims to establish a Proteogenomic Data Analysis Center at the University of Michigan for the Clinical Proteomic Tumor Analysis Consortium (CPTAC). Our center is anchored at the Michigan Center for Translational Pathology and brings together a multi-disciplinary team of leading scientific experts in the foundational areas of proteomics, cancer genomics, immunomics, and integrative systems biology.
Our team established the foundations for precision oncology and proteogenomics at the University of Michigan and has a long history of successful inter-institutional collaborations. This positions us well to apply, working in close collaboration with other CPTAC groups, our innovative algorithms, comprehensive computational infrastructure, and expert knowledge to carry out high-impact translational proteogenomics research that is a core mission of the CPTAC.
We have developed a balanced approach for integrative proteogenomic analyses, with a blend of both state-of-the-art and novel pipelines and tools. Our analytics support dual purpose - to perform both cohort-wide and patient-centric (personalized) investigations – a unique future and a strength of our proposal.
Our experience in support of our real-time precision oncology program and past CPTAC efforts will ensure both the fidelity of detecting diverse proteogenomic cancer driver events and rigorous ascertainment of their biological implications. Both of these features are of paramount importance to understand disease mechanisms and discover prognostic markers and therapeutic targets.
Our proposed strategy combines well-established and innovative data analyses and modeling approaches, cognizant of continuing developments in the corresponding areas. In addition, we propose a conceptually novel approach of "Integrative Cellular Network Analysis" and advanced data visualization modules, capitalizing on recent advances in single-cell and spatial proteogenomics research.
These features will refine inference from the bulk tissue omics data in terms of tumor microenvironment, ploidy and cellularity, identification of cell of origin and clonal expansion, cell-cell interactions, distinguishing lineage versus cancer-specific biomarkers, and gene signatures associated with genetic and epigenetic alterations. Such precise and refined integrative analyses across genome and proteome data require advanced bioinformatics tools and stringent quality control measures.
Our integrated genome/transcriptome/proteome pipelines – already in wide use by the research community - will be further optimized for speed and accuracy and enhanced with data visualization and report generation capabilities for presenting the findings to cancer biologists in a transparent and readily-interpreted manner.
Furthermore, our extensive experience in the area of biomarker discovery and precision oncology, further enhanced through participation of our investigators in the EDRN, SPORE, and other NIH initiatives, puts us in a strong position to drive the biomarker prioritization work to select candidate cancer-specific proteins and peptides for subsequent targeted validation assays.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding Agency
Place of Performance
Ann Arbor,
Michigan
481091276
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 376% from $768,826 to $3,656,494.
Regents Of The University Of Michigan was awarded
Michigan Center for Translational Cancer Proteogenomics
Cooperative Agreement U24CA271037
worth $3,656,494
from the National Institute of Allergy and Infectious Diseases in June 2022 with work to be completed primarily in Ann Arbor Michigan United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.310 Trans-NIH Research Support.
The Cooperative Agreement was awarded through grant opportunity Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).
Status
(Ongoing)
Last Modified 9/5/25
Period of Performance
6/6/22
Start Date
5/31/27
End Date
Funding Split
$3.7M
Federal Obligation
$0.0
Non-Federal Obligation
$3.7M
Total Obligated
Activity Timeline
Transaction History
Modifications to U24CA271037
Additional Detail
Award ID FAIN
U24CA271037
SAI Number
U24CA271037-3919450091
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NC00 NIH National Cancer Institute
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
GNJ7BBP73WE9
Awardee CAGE
03399
Performance District
MI-06
Senators
Debbie Stabenow
Gary Peters
Gary Peters
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,643,044 | 100% |
Modified: 9/5/25